Peroxisome proliferator-activated receptor gamma (PPARc) has previously been implicated in the pathogenesis of follicular thyroid carcinoma (FTC) , where a translocation with PAX8 has been reported in some 50% of tumors in three small series. The resultant fusion protein inhibits normal PPARc function by a dominantnegative mechanism. In a series of 19 FTCs, we identified this translocation in only two tumors (10.5%). However, microarray analysis and semiquantitative RT-PCR demonstrated greatly reduced PPARc expression in 13 of 17 (76%) nontranslocation tumors. Immunohistochemical analysis of 142 thyroid tumors showed a statistically significant reduction in PPARc immunoreactive protein, not only in FTCs but also in papillary thyroid carcinomas and Hurthle cell carcinomas. This suggests that while the overall frequency of the PAX8-PPARc translocation in FTCs may be lower than previously thought, functional downregulation of PPARc is a key event in multiple types of thyroid neoplasia and is a possible target for therapeutic intervention. Oncogene (2003 Oncogene ( ) 22, 3412-3416. doi:10.1038 Keywords: follicular thyroid cancer; microarray analysis Sporadic follicular thyroid cancer (FTC) is relatively uncommon in the general population and the etiology remains poorly understood. Loss of heterozygosity (LOH) has been reported in multiple genomic regions, particularly chromosomes 2, 3p, 7q, 10q and 17p (Zedenius et al., 1996; Grebe et al., 1997; Tung et al., 1997; Ward et al., 1998; Trovato et al., 1999; Yeh et al., 1999; Oriola et al., 2001) , but mutations in candidate tumor suppressor genes, such as VHL, PTEN and TP53 are rare (Dahia et al., 1997; Grebe et al., 1997; Halachmi et al., 1998) . Perhaps, the most significant finding to date has been a translocation between PAX8 at 2q13 and the peroxisome proliferator-activated receptor gamma (PPARg) at 3p25 (Kroll et al., 2000; Marques et al., 2002; Nikiforova et al., 2002) . PPARg is a member of the nuclear hormone receptor superfamily that heterodimerizes with the retinoid X receptor upon ligand binding. Ligands include naturally occurring 15-deoxy-D 12,14 prostaglandin J2 (PGJ2) and the thiazolidinedione (TZD) class of antidiabetic drugs. In addition to its important role in adipocyte differentiation, PPARg has been shown to exert antiproliferative or apoptotic effects on several cancer cell lines (reviewed in Clay et al., 2000) . Somatic loss of function mutations have been identified in sporadic primary colorectal carcinomas (Sarraf et al., 1999) and polymorphisms have been implicated as risk factors for glioblastoma multiforme, endometrial carcinoma and renal cell carcinoma (Zhou et al., 2000; Smith et al., 2001 ). There are two major isoforms, PPARg1 encoded by exons 1-6 and PPARg2 with a unique additional 84 amino acids at the Nterminus encoded by exon II (Elbrecht et al., 1996) . The PAX8-PPARg translocation places transcriptional regulation of PPARg1 under the promoter of PAX8 (Kroll et al., 2000) , a transcription factor that is essential for thyroid differentiation. As a result, PPARg1 is upregulated at the mRNA level. However, the fusion protein acts as a dominant-negative inhibitor of normal PPARg function (Kroll et al., 2000) .
To further investigate the etiology of FTC, we embarked upon a microarray expression comparison of tumors and normal thyroid tissue using the Affymetrix GeneChip system. RNA was extracted by standard methods from a panel of 19 FTCs and prescreened for the presence of a PAX8-PPARg fusion transcript by RT-PCR, as previously described (Kroll et al., 2000) . Two of the 19 tumors (10.5%) were positive. In pilot microarray experiments on six FTCs, data from the PPARg probe-set were then examined specifically for evidence of upregulation in the two translocation-positive samples. This was confirmed, but unexpectedly, the nontranslocation tumors showed downregulation of PPARg in comparison with normal thyroid. We therefore conducted fluorescent semiquantitative RT-PCR in all 19 FTCs and 14 normal thyroid samples to obtain peak height ratios for PPARg normalized to GAPDH (Figure 1 ). Normal samples fell into two distinct groups with nonoverlapping standard deviations: the mean of group 1 was 0.5670.08, while the mean of group 2 was exactly doubled at 1.10710.16. This was not found to be correlated with the polymorphism in exon II and the basis of this bivariate distribution is presently unclear. Thus for the purposes of comparison with tumor samples, normals were considered as one group with a mean ratio of 0.7970.30. Tumors with the translocation showed ratios of 2.00 and 5.25, respectively, at least four standard deviations above the normal mean. Conversely, the group of 17 nontranslocation tumors had a mean ratio of 0.1270.13, significantly different from the mean of the normal group (t ¼ 8.33, Po0.001 with 29 degrees of freedom). Of the 17 nontranslocation tumors, 13 (76%) showed a ratio that fell more than two standard deviations below the normal mean (Table 1a) . Figure 1 Duplex semiquantitative RT-PCR of GAPDH (left peak) and PPARg (right). Random hexamer primed cDNA was PCR amplified for 24 cycles in a 20 ml reaction using 1 mm PPARg primers (TCTGGCCCACCAACTTTGGG and 6FAM-CTTCA-CAAGCATGAACTCCA) and 0.25 mm GAPDH primers (6FAM-CAACTACATGGTTTACATGTTC and GCCAGTGGACTC-CACGAC). Samples were then evaporated to dryness, resuspended in 3 ml of formamide loading buffer and a 1.5 ml aliquot loaded onto an ABI377 genotyping gel (Applied Biosystems, Foster City, CA, USA). Peaks are labeled with the peak height. Top panel, normal thyroid shows approximately equal peak heights; center panel, FTC from the same patient shows significant reduction in PPARg, lower panel, a tumor harboring the translocation shows significant upregulation of PPARg compared to GAPDH Since loss of heterozygosity on 3p has previously been reported in FTCs, LOH analysis was performed with the microsatellite markers D3S1259 and D3S3701, which flank PPARg, as previously described (Yeh et al., 1999) . Three tumors showed LOH for both markers. Two tumors showed LOH at D2S1259 but were uninformative for D3S3701, and thus the status at PPARg is uncertain. One further tumor showed a single allele at both loci, but no paired normal sample was available to determine whether the patient was constitutionally heterozygous. The overall rate of LOH is therefore estimated between 16 and 32%, indicating that this is likely not the major mechanism by which PPARg is downregulated. Furthermore, no mutations were identified in exons 1-6 or exon II of PPARg by direct sequencing of tumor DNA.
To examine a larger number of tumors and determine the effect on PPARg protein levels, immunohistochemistry was then performed on paraffin-embedded or frozen tissue sections using an anti-PPARg mouse monoclonal antibody (Figure 2) . A total of 142 sections were analysed, as detailed in Table 1b , including 17 of the 19 FTCs used for RT-PCR analysis, additional independent cases accrued through the Department of Pathology, The Ohio State University and a commercial human thyroid cancer tissue array (Imgenex IMH-319). Controls were derived from normal post-mortem thyroid specimens and normal tissue adjacent to tumors. Slides were scored for the presence or absence of nuclear staining and results were analysed for statistically significant differences using two-tailed Fisher's exact test. A P-value of less than 0.05 was considered significant.
Specific immunostaining was observed at a moderate level in nuclei of follicular epithelial cells of all seven normal thyroid samples examined. The PAX8-PPARg fusion protein is detected by this antibody and both tumors known to harbor the translocation showed very strong nuclear staining, consistent with the mRNA upregulation already demonstrated (Figure 2c) . A similarly strong immunoreactivity was seen in one additional FTC and three anaplastic thyroid carcinomas (ATCs) in the extended tumor panel, but RNA was not available to confirm whether these carry the translocation. In contrast, an overall majority of tumors were negative for PPARg immunoreactivity ( Figure 2b ). As detailed in Table 1b , this trend was highly statistically significant for all histological types except for ATCs and minimally invasive Hurthle cell carcinomas.
PPARg has previously been implicated in the pathogenesis of follicular thyroid neoplasia (Kroll et al., 2000; Marques et al., 2002; Nikiforova et al., 2002) , as well as other cancers (Sarraf et al., 1999) . However, the FTC studies have focused primarily on the PAX8-PPARg translocation, reported in B50% of FTCs in three small series (Kroll et al., 2000; Marques et al., 2002; Nikiforova et al., 2002) . In the present study, however, a fusion transcript was detected in only two tumors (10.5%), despite using nested PCR under the same conditions as the original report (Kroll et al., 2000) . Except for four frozen FTC tumor sections, all tissues were paraffin embedded and most were analysed as components of tissue microarrays. Normal thyroid sections were included in each experiment as positive controls. Following dewaxing with xylene and antigen retrieval in citric acid buffer for 30 min at 941C, the PPARg (E8) mouse monoclonal antibody (sc-7273, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) was incubated at a dilution of one in 12 for 1 h at 371C. Detection was by the LSAB2 streptavidin-horseradish peroxidase system (DAKO Corp., Carpinteria, CA, USA) and counterstaining with hematoxylin l. Slides were scored for the presence or absence of nuclear staining and the intensity of staining was compared to the normal control from the same experiment. (a) normal thyroid shows moderate staining in the nucleus; (b) FTC with complete absence of staining; and (c) translocation-positive FTC shows very strong nuclear staining Nikiforova et al. (2002) have previously shown a perfect correlation between detection of a fusion transcript by RT-PCR and strong nuclear PPARg immunoreactivity. Our studies showed the same concordance, suggesting that the lower translocation frequency we observed is genuine and not because of technical deficiencies. Since our samples were predominantly obtained from one hospital in Germany, we considered whether our results might reflect geographical variation in the incidence of the translocation among FTCs. However, immunohistochemical analysis of an additional 35 FTCs (including insular type tumors) procured mainly in the US identified only one additional tumor with very strong nuclear staining comparable to that observed in known translocation-positive tumors. This suggests that our results do not reflect geographical differences and that the frequency of the translocation may be generally lower than previously thought. This difference may be because of the smaller numbers of tumors in earlier studies or, in view of suggestion that FTCs harboring the translocation may be more overtly invasive (Nikiforova et al., 2002) , may reflect ascertainment bias. Further large-scale studies are required at both the mRNA and protein level to fully resolve these issues.
Prompted by our low translocation frequency and unexpected results in a pilot microarray experiment, we chose to examine PPARg expression in translocationnegative FTCs. We demonstrated a significant reduction in both PPARg mRNA and immunoreactive protein in the majority of such tumors when compared to normal thyroid. Notably, similar highly significant results were also found in papillary thyroid carcinomas (PTCs) and Hurthle cell carcinomas by immunohistochemistry. In support of this, an absence of PPARg expression has previously been documented in the PTC cell line NPA (Martelli et al., 2002) . Conversely, Ohta et al. (2001) reported that PPARg was upregulated in four of six PTC cell lines and three of six primary PTC tumors. However, as these authors failed to detect PPARg expression in normal thyroid, it is unclear whether the results can be directly compared to our own and other studies (Martelli et al., 2002) , where expression in normal thyroid has been clearly demonstrated. Further investigations by RT-PCR, Western blotting and functional analysis will be required to confirm the extent of PPARg downregulation in all thyroid tumor types. However, these data suggest that downregulation of PPARg function is a key event in thyroid carcinogenesis and is not confined to follicular histologies.
A notable exception was the small group of ATCs, which were mostly positive on immunohistochemistry. Since RNA was not available from these tumors, it is unclear whether this represents a high frequency of the translocation or whether PPARg expression is upregulated by some other mechanism. The translocation has not previously been reported in ATC, although the numbers studied remain small (Marques et al., 2002; Nikiforova et al., 2002) . Furthermore, upregulation of PPARg mRNA has been demonstrated in one ATC cell line without a translocation (Martelli et al., 2002) . This cell line showed marked growth suppression when treated with the PPARg agonist ciglitazone. ATCs have an extremely poor prognosis and further studies of PPARg status in these tumors may provide important insight into their pathogenesis and management.
The mechanisms of PPARg downregulation are only partly known. The dominant-negative effect of the PAX8-PPARg translocation is responsible in a subset of FTCs but not PTCs (Kroll et al., 2000; Marques et al., 2002; Nikiforova et al., 2002) . High rates of LOH on 3p have been reported in oxyphilic FTCs (Grebe et al., 1997) , but we observed LOH of the PPARg region in only one-third of nonoxyphilic FTC tumors. Furthermore, we did not identify any mutations in 17 FTCs by direct sequencing of the PPARg gene and no CpG island could be identified that might be a target for hypermethylation. Downregulation of PPARg is likely therefore secondary to effects on upstream regulatory proteins, stability of transcript or protein, or some other as yet undetermined genetic or epigenetic mechanism.
In conclusion, this study suggests that functional downregulation of PPARg is a common mechanism in the etiology of thyroid carcinogenesis and is not restricted to FTCs. While this precludes the use of PPARg as a tool for differential diagnosis, it suggests that therapeutic use of PPARg ligands in the treatment of thyroid neoplasia may be widely applicable. The PPARg agonists troglitazone, BRL49653, ciglitazone and PGJ2 have been shown to induce in vitro growth suppression and apoptosis in several PTC, ATC and FTC cell lines that express or overexpress PPARg (Ohta et al., 2001; Martelli et al., 2002) , while troglitazone also inhibited tumor growth and metastasis when PTC lines were injected into nude mice (Ohta et al., 2001) . It is not immediately clear whether in vivo human thyroid tumors that are downregulated for PPARg have sufficient residual activity to benefit from stimulation by TZDs or PGJ2. However, the possible use of these drugs in the treatment of advanced and metastatic thyroid carcinoma of all histological types warrants further investigation.
